Abstract 431: Malic enzyme 2 inhibition reveals metabolic vulnerability in serine-dependent triple-negative breast cancer

Slayton et al. (Fri,) studied this question.

www.synapsesocial.com/papers/68e72f48b6db6435876a8570 — DOI: https://doi.org/10.1158/1538-7445.am2024-431

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Interplay between malic enzyme 2, de novo serine synthesis, and the malate-aspartate shuttle drives metabolic adaptation in triple-negative breast cancer· 2025
2. Abstract 2412: Malic enzyme inhibition as a strategy to exploit metabolic reprogramming in cancer: A structure-based approach· 2026
3. Abstract 7151: Targeting metabolic pathway in triple negative breast cancer with a small molecule inhibitor· 2024
4. Abstract 2009: Targeting metabolic vulnerabilities in basal-like breast cancer.· 2026
5. Abstract PS3-12-22: Tumor cell AADAT suppresses CD8+T cell function by depleting malate, driving progression in Triple-Negative Breast Cancer· 2026